- About this Journal ·
- Abstracting and Indexing ·
- Aims and Scope ·
- Annual Issues ·
- Article Processing Charges ·
- Articles in Press ·
- Author Guidelines ·
- Bibliographic Information ·
- Citations to this Journal ·
- Contact Information ·
- Editorial Board ·
- Editorial Workflow ·
- Free eTOC Alerts ·
- Publication Ethics ·
- Reviewers Acknowledgment ·
- Submit a Manuscript ·
- Subscription Information ·
- Table of Contents
BioMed Research International
Volume 2014 (2014), Article ID 696107, 10 pages
Induction of Apoptosis in Human Multiple Myeloma Cell Lines by Ebselen via Enhancing the Endogenous Reactive Oxygen Species Production
Cancer Center, Research Institute of Surgery, Daping Hospital, Third Military Medical University, 10 Changjiang Zhi Road, Daping Yuzhong District, Chongqing 400042, China
Received 26 April 2013; Revised 10 October 2013; Accepted 10 October 2013; Published 27 January 2014
Academic Editor: Xin-yuan Guan
Copyright © 2014 Liang Zhang et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
- A. Muller, E. Cadenas, P. Graf, and H. Sies, “A novel biologically active seleno-organic compound—I. Glutathione peroxidase-like activity in vitro and antioxidant capacity of PZ 51 (Ebselen),” Biochemical Pharmacology, vol. 33, no. 20, pp. 3235–3239, 1984.
- P. Chew, D. Y. C. Yuen, N. Stefanovic et al., “Antiatherosclerotic and renoprotective effects of ebselen in the diabetic apolipoprotein E/GPx1-double knockout mouse,” Diabetes, vol. 59, no. 12, pp. 3198–3207, 2010.
- F. Basarslan, N. Yilmaz, I. Davarci, et al., “Effects of ebselen on radiocontrast media-induced hepatotoxicity in rats,” Toxicology and Industrial Health, vol. 29, no. 8, pp. 746–752, 2013.
- Y. Poyrazoglu, T. Yigit, A. Harlak et al., “Effects of prevention of oxidative and nitro-oxidative stress on experimental rat colon anastomosis using acetylcysteine, ebselen and 1400w,” Acta Chirurgica Belgica, vol. 111, no. 1, pp. 26–31, 2011.
- T. Tunc, B. Uysal, C. Atabek et al., “Erdosteine and ebselen as useful agents in intestinal ischemia/reperfusion injury,” Journal of Surgical Research, vol. 155, no. 2, pp. 210–216, 2009.
- M. Kizilgun, Y. Poyrazoglu, Y. Oztas et al., “Beneficial effects of N-acetylcysteine and ebselen on renal ischemia/reperfusion injury,” Renal Failure, vol. 33, no. 5, pp. 512–517, 2011.
- Z. Yin, E. Lee, M. Ni et al., “Methylmercury-induced alterations in astrocyte functions are attenuated by ebselen,” NeuroToxicology, vol. 32, no. 3, pp. 291–299, 2011.
- H. Koizumi, H. Fujisawa, E. Suehiro, S. Shirao, and M. Suzuki, “Neuroprotective effects of ebselen following forebrain ischemia: involvement of glutamate and nitric oxide,” Neurologia Medico-Chirurgica, vol. 51, no. 5, pp. 337–343, 2011.
- J. Y. Seo, C. H. Lee, J. H. Cho et al., “Neuroprotection of ebselen against ischemia/reperfusion injury involves GABA shunt enzymes,” Journal of the Neurological Sciences, vol. 285, no. 1-2, pp. 88–94, 2009.
- J. Lu, C. Berndt, and A. Holmgren, “Metabolism of selenium compounds catalyzed by the mammalian selenoprotein thioredoxin reductase,” Biochimica et Biophysica Acta, vol. 1790, no. 11, pp. 1513–1519, 2009.
- R. Zhao and A. Holmgren, “A novel antioxidant mechanism of ebselen involving ebselen diselenide, a substrate of mammalian thioredoxin and thioredoxin reductase,” Journal of Biological Chemistry, vol. 277, no. 42, pp. 39456–39462, 2002.
- A. Muller, H. Gabriel, H. Sies, R. Terlinden, H. Fischer, and A. Romer, “A novel biologically active selenoorganic compound-VII. Biotransformation of ebselen in perfused rat liver,” Biochemical Pharmacology, vol. 37, no. 6, pp. 1103–1109, 1988.
- H. Shi, S. Liu, M. Miyake, and K. J. Liu, “Ebselen induced C6 glioma cell death in oxygen and glucose deprivation,” Chemical Research in Toxicology, vol. 19, no. 5, pp. 655–660, 2006.
- L. Engman, I. Cotgreave, M. Angulo, C. W. Taylor, G. D. Paine-Murrieta, and G. Powis, “Diaryl chalcogenides as selective inhibitors of thioredoxin reductase and potential antitumor agents,” Anticancer Research, vol. 17, no. 6, pp. 4599–4605, 1997.
- C.-F. Yang, H.-M. Shen, and C.-N. Ong, “Ebselen induces apoptosis in HepG2 cells through rapid depletion of intracellular thiols,” Archives of Biochemistry and Biophysics, vol. 374, no. 2, pp. 142–152, 2000.
- P. J. Guérin and E. R. Gauthier, “Induction of cellular necrosis by the glutathione peroxidase mimetic ebselen,” Journal of Cellular Biochemistry, vol. 89, no. 1, pp. 203–211, 2003.
- J. K. Brunelle and A. Letai, “Control of mitochondrial apoptosis by the Bcl-2 family,” Journal of Cell Science, vol. 122, part 4, pp. 437–441, 2009.
- D. J. Allan, A. Howell, S. A. Roberts et al., “Reduction in apoptosis relative to mitosis in histologically normal epithelium accompanies fibrocystic change and carcinoma of the premenopausal human breast,” Journal of Pathology, vol. 167, no. 1, pp. 25–32, 1992.
- H.-U. Simon, A. Haj-Yehia, and F. Levi-Schaffer, “Role of reactive oxygen species (ROS) in apoptosis induction,” Apoptosis, vol. 5, no. 5, pp. 415–418, 2000.
- L. Behrend, G. Henderson, and R. M. Zwacka, “Reactive oxygen species in oncogenic transformation,” Biochemical Society Transactions, vol. 31, part 6, pp. 1441–1444, 2003.
- S. Toyokuni, “Persistent oxidative stress in cancer,” FEBS Letters, vol. 358, no. 1, pp. 1–3, 1995.
- M. Gomez-Lazaro, M. F. Galindo, R. M. Melero-Fernandez De Mera et al., “Reactive oxygen species and p38 mitogen-activated protein kinase activate bax to induce mitochondrial cytochrome c release and apoptosis in response to malonate,” Molecular Pharmacology, vol. 71, no. 3, pp. 736–743, 2007.
- A. Mahindra, T. Hideshima, and K. C. Anderson, “Multiple myeloma: biology of the disease,” Blood Reviews, vol. 24, supplement 1, pp. S5–S11, 2010.
- C. P. Austin, L. S. Brady, T. R. Insel, and F. S. Collins, “NIH molecular libraries initiative,” Science, vol. 306, no. 5699, pp. 1138–1139, 2004.
- F. C. Meotti, V. C. Borges, G. Zeni, J. B. T. Rocha, and C. W. Nogueira, “Potential renal and hepatic toxicity of diphenyl diselenide, diphenyl ditelluride and ebselen for rats and mice,” Toxicology Letters, vol. 143, no. 1, pp. 9–16, 2003.
- T. Yamaguchi, K. Sano, K. Takakura et al., “Ebselen in acute ischemic stroke: a placebo-controlled, double-blind clinical trial,” Stroke, vol. 29, no. 1, pp. 12–17, 1998.
- T. Ozgur, M. Tutanc, I. Zararsiz, et al., “The protective effect of ebselen on radiocontrast-induced nephrotoxicity,” Renal Failure, vol. 34, no. 8, pp. 991–997, 2012.
- V. Sharma, R. Tewari, U. H. Sk, C. Joseph, and E. Sen, “Ebselen sensitizes glioblastoma cells to Tumor Necrosis Factor (TNFα)-induced apoptosis through two distinct pathways involving NF-κB downregulation and Fas-mediated formation of death inducing signaling complex,” International Journal of Cancer, vol. 123, no. 9, pp. 2204–2212, 2008.
- T. Maraldi, C. Prata, D. Fiorentini, L. Zambonin, L. Landi, and G. Hakim, “Induction of apoptosis in a human leukemic cell line via reactive oxygen species modulation by antioxidants,” Free Radical Biology and Medicine, vol. 46, no. 2, pp. 244–252, 2009.
- R. L. Puntel, D. H. Roos, R. L. Seeger, et al., “Mitochondrial electron transfer chain complexes inhibition by different organochalcogens,” Toxicology in Vitro, vol. 27, no. 1, pp. 59–70, 2013.
- R. L. Puntel, D. H. Roos, R. L. Seeger, et al., “Organochalcogens inhibit mitochondrial complexes I and II in rat brain: possible implications for neurotoxicity,” Neurotoxicity Research, vol. 24, no. 2, pp. 109–118, 2013.
- R. L. Puntel, D. H. Roos, V. Folmer et al., “Mitochondrial dysfunction induced by different organochalchogens is mediated by thiol oxidation and is not dependent of the classical mitochondrial permeability transition pore opening,” Toxicological Sciences, vol. 117, no. 1, pp. 133–143, 2010.
- R. Zhao, H. Masayasu, and A. Holmgren, “Ebselen: a substrate for human thioredoxin reductase strongly stimulating its hydroperoxide reductase activity and a superfast thioredoxin oxidant,” Proceedings of the National Academy of Sciences of the United States of America, vol. 99, no. 13, pp. 8579–8584, 2002.
- D. Morin, R. Zini, H. Ligeret, W. Neckameyer, S. Labidalle, and J.-P. Tillement, “Dual effect of ebselen on mitochondrial permeability transition,” Biochemical Pharmacology, vol. 65, no. 10, pp. 1643–1651, 2003.
- L. P. Billen, C. L. Kokoski, J. F. Lovell, B. Leber, and D. W. Andrews, “Bcl-XL inhibits membrane permeabilization by competing with Bax,” PLoS Biology, vol. 6, no. 6, article e147, 2008.
- X. Wang, “The expanding role of mitochondria in apoptosis,” Genes and Development, vol. 15, no. 22, pp. 2922–2933, 2001.
- S. Antony and C. A. Bayse, “Modeling the mechanism of the glutathione peroxidase mimic ebselen,” Inorganic Chemistry, vol. 50, no. 23, pp. 12075–12084, 2011.
- B. K. Sarma and G. Mugesh, “Antioxidant activity of the anti-inflammatory compound ebselen: a reversible cyclization pathway via selenenic and seleninic acid intermediates,” Chemistry, vol. 14, no. 34, pp. 10603–10614, 2008.
- C. W. Nogueira and J. B. T. Rocha, “Toxicology and pharmacology of selenium: emphasis on synthetic organoselenium compounds,” Archives of Toxicology, vol. 85, no. 11, pp. 1313–1359, 2011.
- S. M. Deneke, “Thiol-based antioxidants,” Current Topics in Cellular Regulation, vol. 36, pp. 151–180, 2001.
- R. L. Puntel, D. H. Roos, R. L. Seeger, and J. B.T. Rocha, “Mitochondrial electron transfer chain complexes inhibition by different organochalcogens,” Toxicology in Vitro, vol. 27, no. 1, pp. 59–70, 2013.
- J. P. Fruehauf and F. L. Meyskens Jr., “Reactive oxygen species: a breath of life or death?” Clinical Cancer Research, vol. 13, no. 3, pp. 789–794, 2007.
- P. T. Schumacker, “Reactive oxygen species in cancer cells: live by the sword, die by the sword,” Cancer Cell, vol. 10, no. 3, pp. 175–176, 2006.
- S.-J. Kim, C. Park, A. L. Han et al., “Ebselen attenuates cisplatin-induced ROS generation through Nrf2 activation in auditory cells,” Hearing Research, vol. 251, no. 1-2, pp. 70–82, 2009.
- E. D. Lynch, R. Gu, C. Pierce, and J. Kil, “Reduction of acute cisplatin ototoxicity and nephrotoxicity in rats by oral administration of allopurinol and ebselen,” Hearing Research, vol. 201, no. 1-2, pp. 81–89, 2005.
- D. Hardej and L. D. Trombetta, “The effects of ebselen on cisplatin and diethyldithiocarbamate (DDC) cytotoxicity in rat hippocampal astrocytes,” Toxicology Letters, vol. 131, no. 3, pp. 215–226, 2002.
- M. Yoshida, K. Iizuka, A. Terada et al., “Prevention of nephrotoxicity of cisplatin by repeated oral administration of ebselen in rats,” Tohoku Journal of Experimental Medicine, vol. 191, no. 4, pp. 209–220, 2000.
- K. Husain, C. Morris, C. Whitworth, G. L. Trammell, L. P. Rybak, and S. M. Somani, “Protection by ebselen against cisplatin-induced nephrotoxicity: antioxidant system,” Molecular and Cellular Biochemistry, vol. 178, no. 1-2, pp. 127–133, 1998.
- G. S. Baldew, A. P. Boymans, J. G. J. Mol, and N. P. E. Vermeulen, “The influence of ebselen on the toxicity of cisplatin in LLC-PK1 cells,” Biochemical Pharmacology, vol. 44, no. 2, pp. 382–387, 1992.
- G. S. Baldew, J. G. McVie, M. A. van der Valk, G. Los, J. J. M. de Goeij, and N. P. E. Vermeulen, “Selective reduction of cis-diamminedichloroplatinum(II) nephrotoxicity by ebselen,” Cancer Research, vol. 50, no. 21, pp. 7031–7036, 1990.
- S. Y. Saad, T. A. Najjar, and M. M. Arafah, “Cardioprotective effects of subcutaneous ebselen against daunorubicin-induced cardiomyopathy in rats,” Basic and Clinical Pharmacology and Toxicology, vol. 99, no. 6, pp. 412–417, 2006.
- D. N. Tripathi and G. B. Jena, “Ebselen attenuates cyclophosphamide-induced oxidative stress and DNA damage in mice,” Free Radical Research, vol. 42, no. 11-12, pp. 966–977, 2008.
- S. Kotamraju, E. A. Konorev, J. Joseph, and B. Kalyanaraman, “Doxorubicin-induced apoptosis in endothelial cells and cardiomyocytes is ameliorated by nitrone spin traps and ebselen. Role of reactive oxygen and nitrogen species,” Journal of Biological Chemistry, vol. 275, no. 43, pp. 33585–33592, 2000.
- E. D. Lynch, R. Gu, C. Pierce, and J. Kil, “Combined oral delivery of ebselen and allopurinol reduces multiple cisplatin toxicities in rat breast and ovarian cancer models while enhancing anti-tumor activity,” Anti-Cancer Drugs, vol. 16, no. 5, pp. 569–579, 2005.